ReviewBlood neoplasia2025
Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma.
Review in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Survival: Measuring Treatment Tolerability with Patient-Reported Outcomes in the Lymphoma Immunotherapy Era.Current hematologic malignancy reports · 2026Review
- Predictors of sensitivity to immune therapies in classic Hodgkin lymphoma.Blood neoplasia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized therapy for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Some patients discontinue ICIs after initial response or owing to immune-related adverse events (AEs). Efficacy and safety of ICI rechallenge, defined as reintroducing ICIs after previous discontinuation, remain unclear. A systematic literature search was performed through 10 January 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD42023403204). Studies reporting outcomes of ICI rechallenge in patients with R/R HL were included. Data on overall response rate (ORR), complete response (CR) rate, progression-free survival (PFS), and treatment-related AEs were extracted. Pooled response rates and 95% confidence intervals (CIs) were calculated. A total of 207 patients from 17 studies were included. The pooled ORR was 63% (95% CI, 55-70) with a CR rate of 43% (95% CI, 35-52). Median PFS after rechallenge was 13.3 months (95% CI, 7.9-18.8). Any-grade and grade 3 to 5 AEs occurred in 47% (95% CI, 17-80) and 31% (95% CI, 23-40), respectively. ICI rechallenge in R/R classic HL can lead to high response rates and durable remissions comparable with uninterrupted ICI therapy with acceptable safety profiles. This strategy may be a viable option, although careful patient selection and monitoring are still necessary.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.